000			01781nam a2200145 4500
008			250718b |||||||| |||| 00| 0 eng d
100			_aMeghraj Suryawansh
245			_aFORMULATION AND IN VITRO EVALUATION OF SUBLINGUAL TABLETS OF PIROXICAM
300			_app33-40
520			_aThis study focuses on the development and evaluation of sublingual tablets for piroxicam, aiming to enhance its bioavailability and patient compliance. Preformulation studies confirmed the drug’s identity and purity through melting point analysis, UV-Vis spectroscopy and FT-IR, while solubility test highlights its low solubility in water and buffer, but higher solubility in ethanol. Formulation strategies incorporated varying microcrystalline cellulose (MCC) to polymer or to super disintegrant ratios to improve blend flow and compressibility. Among the formulations tested, A4, containing 5% Kyron T-314, emerged as the most optimized formulation, showing the best pre-compression and post-compression characteristics. It demonstrated superior hardness, low friability, rapid wetting and disintegration times, and achieved nearly complete drug release within 9 minutes. Stability studies over three months confirmed that formulation A4 maintained its physical and mechanical properties. Hence, this formulation is considered highly effective for achieving rapid drug release and improved stability, addressing the need for quicker onset of action and enhanced patient adherence.
654			_aContact dermatitis _aSevyachanadi lepa _aSparshaja visha _aGas chromatography-mass spectrometry analysis _aanti-inflammatory _aantioxidant
700			_aJailani S
773	0		_0125265 _9112973 _dMumbai Indian Drugs Manufacturer's Association _tIndian Drugs _x0019-462X
942			_cJA
999			_c132134 _d132134